INCY · Incyte Corporation
$115.71
-1.04% last session
End-of-day data · close of 2026-10-23
Market cap
$23B
Enterprise value
$19B
Trailing P/E
14.7
Forward P/E
13.3
Dividend yield
0.0%
Beta
0.74
Avg volume
2M
Employees
3K
Daily Change %
-1.04%
5 Days Change
3.41%
10 Days Change
7.65%
30 Days Change
-6.19%
60 Days Change
-8.63%
Month to Day Change
-0.18%
Year to Day Change
18.39%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — INCY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-21
Latest call per bank · past 12 months
RBC Capital
Sector Perform$114
-1.5% vs priceWells Fargo
Equal-Weight$128
+10.6% vs priceJP Morgan
Neutral$123
+6.3% vs priceBarclays
Overweight$139
+20.1% vs priceMorgan Stanley
Equal-Weight$104
-10.1% vs priceUBS
Neutral$113
-2.3% vs priceJefferies
Hold$94.00
-18.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Maintains | Buy | $138 → $140 |
| 2026-10-14 | Truist Securities | Maintains | Hold | $105 → $115 |
| 2026-10-13 | HC Wainwright & Co. | Reiterates | Buy | $152 |
| 2026-10-08 | RBC Capital | Maintains | Sector Perform | $109 → $114 |
| 2026-10-05 | Stifel | Maintains | Buy | $145 → $157 |
| 2026-10-01 | Wells Fargo | Maintains | Equal-Weight | $116 → $128 |
| 2026-09-28 | JP Morgan | Maintains | Neutral | $120 → $123 |
| 2026-09-28 | HC Wainwright & Co. | Maintains | Buy | $150 → $152 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 4.6% below the 50-day MA ($121.26).
- bullish: Price vs 200-day MA: Trading 7.4% above the 200-day MA ($107.78).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.63) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($89.31) and high ($129.93).
INCY Price Chart
Loading chart for INCY…
Fundamentals
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.